PRE-EXPOSURE PROPHYLAXIS OF HIV INFECTION

This study tests a new option for preventing HIV: a shot given under the skin every 6 months, called lenacapavir. It compares how well people stick with the shot versus taking a daily pill (Truvada). About 268 people at higher risk for HIV will take part. The goal is to see if th…

This study tested two ways to prevent HIV in over 5,000 adolescent girls and young women at risk. One group received a long-acting shot every six months, while others took daily pills. The goal was to see how well each method works to keep participants HIV-free.

This study looks at a new way to prevent HIV in people who inject drugs. It tests a shot given under the skin every 6 months (lenacapavir) and compares it to daily pills. The goal is to see how well the shot works in the body and if it is safe. About 181 people in the US are taki…

This phase 3 trial tests lenacapavir, a long-acting drug given as a shot every six months, to prevent HIV infection. Over 3,200 participants at risk for HIV received either lenacapavir or daily pills. The goal is to see if the shot is as effective as daily PrEP, offering a more c…

This study tests a new long-acting injection called lenacapavir, given every 6 months, to prevent HIV in cisgender women in the US. About 253 women will receive either the injection or daily pills (Truvada) to compare how well the drug works in the body, its safety, and how accep…